Amivantamab Shows Strong Efficacy in NSCLC With EGFR Exon 20 InsertionByErminia Massarelli, MDSeptember 7th 2022Erminia Massarelli, MD, PhD, MS, discusses the efficacy outcomes of the CHRYSALIS trial of amivantamab in patients with non–small cell lung cancer and an EGFR exon 20 insertion.